Interestingly, immune checkpoints (e.g., LAG3 and CD274) showed an increased expression in patients with FAT mutations, suggesting that FAT mutations might be a cofactor in STAD immunotherapy. This evidence concerns the gene FAT1 and gastric adenocarcinoma.